Jazz Pharmaceuticals and Roche received FDA approval for their combination therapy of Zepzelca (lurbinectedin) and Tecentriq (atezolizumab) as a first-line maintenance treatment in extensive-stage small-cell lung cancer. Based on phase III Imforte study data, the combo reduced disease progression or death risk by 46% and overall mortality by 27% compared to Tecentriq alone. This marks a novel maintenance regimen offering improved outcomes for patients post induction therapy. This approval precedes the sNDA's original October 7 PDUFA date, signaling a potential shift in standard care for this indication.